The medical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s showing significant potential in clinical trials for addressing obesity. Unlike some available weight loss solutions, retatrutide appears to provide a greater substantial reduction in body mass and benefit metabolic markers, particula